Drs Banu Arun and Stephanie Graff discuss drug access, clinical trials, and health disparities in advanced and metastatic breast cancer, and inclusion-based solutions for physicians and institutions.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982650). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Breast Cancer https://emedicine.medscape.com/article/1947145-overview

A Review of Triple-Negative Breast Cancer https://www.medscape.com/viewarticle/727195_4

Oral Selective Estrogen Receptor Degraders (SERDS) as a Novel Breast Cancer Therapy: Present and Future From a Clinical Perspective https://pubmed.ncbi.nlm.nih.gov/34360578/

Introduction to Antibody-Drug Conjugates https://pubmed.ncbi.nlm.nih.gov/34842621/

Sacituzumab Govitecan (Rx) https://reference.medscape.com/drug/trodelvy-sacituzumab-govitecan-1000280

Trastuzumab Deruxtecan (Rx) https://reference.medscape.com/drug/enhertu-trastuzumab-deruxtecan-4000032

T-DM1 https://www.cancer.gov/publications/dictionaries/cancer-terms/def/t-dm1

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update https://pubmed.ncbi.nlm.nih.gov/31928404/

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33882206/

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018 https://pubmed.ncbi.nlm.nih.gov/31415071/

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35665782/

Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35320644/

I-SPY 2: A Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33312344/

Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/35280480/

Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement https://pubmed.ncbi.nlm.nih.gov/35588469/

Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-Assessment https://pubmed.ncbi.nlm.nih.gov/36630663/

An Assessment of the Feasibility and Utility of an ACCC-ASCO Implicit Bias Training Program to Enhance Racial and Ethnic Diversity in Cancer Clinical Trials https://pubmed.ncbi.nlm.nih.gov/36630671/

The Implicit Association Test in Health Professions Education: A Meta-Narrative Review https://pubmed.ncbi.nlm.nih.gov/31535290/

Increasing Black Patient Participation in Metastatic Breast Cancer Clinical Trials: The BECOME (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement) Project https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.1014#

Achieving Culturally Competent Cancer Care: A Qualitative Study Drawing on the Perspectives of Cancer Survivors and Oncology Nurses https://pubmed.ncbi.nlm.nih.gov/31841798/